In vaginal candidosis:

TRADEMARK

Nizoral

ketoconazole

the elegant way to treat an inelegant problem



2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem

Remember:
oral convenience improves patient compliance and so reduces the chance of relapse.

Presentation: white, flat, half-scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Dosage** (for vaginal candidosis only): two tablets (400 mg) once daily for 5 days. For maximal absorption Nizoral should be taken with meals. **Nizoral is contra-indicated in pregnancy.** Precautions: the use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H_2-blockers) should be avoided and, if indicated, such drugs should be taken not less than 2 hours after Nizoral. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. **Side-effects:** nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole; these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment.
Full prescribing information available on request.

References:
Tooley, *et al.*: The Practitioner 229, 655 (1985)
Benussi, *et al.*: Curr. Ther. Res. 31(4), 511 (1982)

JANSSEN
PHARMACEUTICA
B-2340 Beerse, Belgium
world leader in antimycotic research

The power to relieve arthritis

PRESCRIBING INFORMATION:

PRESENTATION: White, convex tablets, 11mm in diameter marked SURGAM 300 on one side and on the reverse. Each tablet contains 300mg tiaprofenic acid.
White, convex tablets, 10mm in diameter, marked SURGAM 200 on one side and on the reverse. Each tablet contains 200mg tiaprofenic acid. Sachets containing 300mg tiaprofenic acid.
Uses *Properties:* Surgam is a non-steroidal anti-inflammatory agent with marked analgesic properties.
Indications: Rheumatoid arthritis, osteoarthritis; ankylosing spondylitis; low back pain; musculo-skeletal disorders such as fibrositis, capsulitis, epicondylitis and other soft-tissue inflammatory conditions: sprains and strains, post-operative inflammation and pain, and other soft-tissue injuries.
Dosage and administration *Adults:* 600mg daily in divided doses. 300mg twice daily. Alternatively, 200mg three times daily.
Elderly: Current research suggests that it is not necessary to modify the dosage of Surgam in the elderly or in cases of mild to moderate renal impairment. In severe renal impairment, it is suggested that the dosage should be reduced to 200mg twice daily.
Children: There are insufficient data to recommend use of Surgam in children.
Contra-indications, warnings etc. *Contra-indications:* Active peptic ulceration, history of peptic ulceration, hypersensitivity to the drug. *Precautions:* Surgam should be used with care in patients with a history of severe renal or hepatic insufficiency, asthma or previous sensitivity to aspirin or other non-steroidal anti-inflammatory agents. Non-steroidal anti-inflammatory drugs may cause some sodium and fluid retention. This should be borne in mind in patients with incipient or actual congestive heart failure. Since Surgam is highly protein-bound, it may be necessary to modify the dosage of other highly protein-bound drugs, e.g. anticoagulants, sulphonamides, hypoglycaemic agents, phenytoin and certain potent diuretics when these are administered concurrently.
Pregnancy: Although animal studies have not revealed evidence of teratogenicity safety in human pregnancy and lactation cannot be assumed and, in common with other non-steroidal anti-inflammatory agents, administration during the first trimester should be avoided.
Lactation: There are no data on the passage of Surgam into the breast milk.
Side effects: Surgam is generally well tolerated. Gastro-intestinal reactions which have been reported include dyspepsia, nausea, abdominal pain, vomiting, anorexia, indigestion, heartburn, stomatitis, constipation, gastritis, flatulence or diarrhoea. In common with other non-steroidal anti-inflammatory agents, peptic ulcers, gastro-intestinal bleeding and perforation have occasionally been reported and in exceptional cases may have been associated with fatalities. Headache and drowsiness have occasionally been reported as have skin reactions, which include rash, photosensitivity, urticaria, pruritis, angio-oedema and alopecia.
Treatment of overdosage: In the event of an overdosage with Surgam, supportive and symptomatic therapy is indicated.
Pharmaceutical precautions Store in a cold place and protect from light.
Legal category Prescription Only Medicine.
Package quantities 300mg tablets in bottles of 60. 200mg tablets in bottles of 100. 300mg sachets in packets of 60.
Basic NHS prices and Product licence numbers Surgam 300mg £15.44 per pack of 60 0109/0109 Surgam 200mg £16.39 per pack of 100 0109/0108 Surgam 300mg sachets £15.44 per pack of 60. 0109/0127
Further information Nil. **Date of preparation** March 1987.

ROUSSEL

SURGAM 300

tiaprofenic acid

bd

Roussel Laboratories Ltd,
Broadwater Park, North Orbital Road,
Uxbridge, Middlesex UB9 5HP.

Three new titles . . .
to be published soon

ABC OF AIDS

EDITED BY MICHAEL W ADLER

Today's most widely known and perhaps the most generally feared disease, AIDS presents particular problems for non-specialist doctors. So far treatment of patients with AIDS has been largely confined to specialist centres so that, although the disease will inevitably spread, few doctors have had much experience of managing it. The *ABC of AIDS* provides essential details on the development of the epidemic, management of early HIV infection, tumours, and the respiratory, neurological, and gastrointestinal manifestations. It discusses the treatment of infections and the prospects for vaccines and prevention as well as outlining programmes for counselling, nursing, and the control of infection. Edited by Michael Adler, a leading authority on the topic, the *ABC of AIDS* is a vital guide that no medical practitioner can afford to be without.

Price: Inland £9.95; Abroad £12.50; USA$21.00
BMA members: Inland £8.95; Abroad £11.50; USA$19.00

ABC OF HYPERTENSION—*Second edition*

A short guide to a complex and rapidly developing topic, the second, revised edition of *ABC of Hypertension* reviews up to date information from all recent clinical trials on hypertension and includes the latest recommendations of the British Hypertension Society. With its comprehensive survey of drug treatment—including advice on treating hypertension in pregnancy and in the elderly—this is an invaluable source of facts and guidance for practising doctors and medical students.

Price: Inland £4.95; Abroad £6.50; USA$10.50
BMA members: Inland £4.45; Abroad £6.00; USA$9.50

ABC OF ALCOHOL

ALEX PATON

One of today's most pressing medical and social problems is comprehensively reviewed in the *ABC of Alcohol.* With an extended introduction by Richard Smith, assistant editor of the *BMJ,* this second, revised and expanded edition brings readers up to date on current approaches to the diagnosis and treatment of alcoholism. Essential reading for all doctors who need to understand the appalling difficulties that this condition creates for patients and their families—and indeed for doctors themselves.

Price: Inland £5.95; Abroad £7.50; USA$13.00
BMA members: Inland £5.45; Abroad £7.00; USA$12.00

Why not order your copies now?

FROM: BRITISH MEDICAL JOURNAL, PO Box 295, London WC1H 9TE

(Please enclose payment with order)

Rocephin

ceftriaxone Trade Mark

24-hour bactericidal power

Once daily parenteral cephalosporin

Highly effective in a broad range of pathogens

Neisseria meningitidis
(human blood agar)

MIC_{50}: ≤ 0.008 µg/ml
MIC_{90}: ≤ 0.008 µg/ml

Proteus mirabilis
(maltose agar)

MIC_{50}: 0.008 µg/ml
MIC_{90}: 0.025 µg/ml

Salmonella typhimuricum
(S.S. agar)



MIC_{50}: 0.007 µg/ml
MIC_{90}: 0.125 µg/ml

Klebsiella pneumoniae
(endo agar)



MIC_{50}: 0.05 µg/ml
MIC_{90}: 0.1 µg/ml

Escherichia coli
(Levine EMB agar)

MIC_{50}: 0

sensitive: ≤8 µg/ml; intermediate: 16–32

Reference
1. Data on file,
F. Hoffmann-La Roche & Co. Limited Company,
Basle, Switzerland.

ROCHE

F. Hoffmann-La Roche &
Limited Company, Basle, Switzerland



Composition: **1 sustained release tablet of Adalat retard contains 20 mg nifedipine.** Indications: 1. Coronary heart disease: Chronic stable angina pectoris (exercise angina), angina pectoris following infarction (except in the first 8 days following an acute myocardial infarction). 2. Hypertension. Contraindications: Hypersensitivity to Adalat retard and the whole period of pregnancy. There are no findings on use during lactation. Caution should be exercised in the presence of pronounced low blood pressure (severe hypotension: systolic blood pressure < 90 mmHg). Cardiovascular shock. Side-effects: Side-effects generally occur at the start of therapy and are often of a slight and transient nature: facial flush, heat sensation, headache. In isolated cases particularly at higher doses: nausea, dizziness, tiredness, skin reactions, paraesthesia, hypotensive reaction, palpitations and increased pulse rate. Occasionally leg oedema due to dilatation of the blood vessels. Extremely rare: during long-term therapy, gingival hyperplasia which regresses completely once therapy is discontinued; chest pain (which may be angina pectoris-like pain) – where this occurs and a causal connection with Adalat is suspected, therapy should be discontinued. Caution should be exercised with dialysis patients with malignant hypertension and irreversible renal failure with hypovolaemia, since vasodilatation can result in a reduction in blood pressure. Treatment of hypertension with this drug requires regular medical supervision. Individuals may react differently to this drug and some patient's ability to drive and to operate machinery may be impaired. This applies particularly at the start of treatment, when changing from one preparation to another and if alcohol is consumed. Mode of action: Adalat retard is a calcium antagonist and is classified as a coronary therapeutic agent/antihypertensive agent. Dosage: Treatment should be adapted to the individual as much as possible according to the severity of the disease and the patient's response to therapy. Dosage guidelines for: Coronary heart disease: Chronic stable angina pectoris (exercise angina), angina pectoris following infarction; hypertension: 2 x daily 1 sustained release tablet Adalat retard. In some cases it may be necessary to increase the dose further to 2 x 2 sustained release tablets (2 x 40 mg). If sufficient therapeutic success is not observed in angina pectoris patients after approximately 14 days of therapy, this treatment should be replaced by the fast-acting (10 mg) Adalat capsule where this is advised by the physician. The tablets should be swallowed whole with a small amount of liquid independently of meals. Dosage interval: 12 hours, but in any case not less than 4 hours. Interactions with other drugs: Adalat retard/antihypertensive agents: concomitant administration may enhance the antihypertensive effect of nifedipine. Adalat retard/beta receptor blockers: the patient must be monitored carefully during concomitant administration since severe hypotension may occur; development of heart failure has been reported occasionally. Adalat retard/cimetidine: possible enhancement of antihypertensive effect. Note: If a particularly rapid onset of action is required for the treatment of spasms of the coronary vessels (coronary spasm: Prinzmetal's angina, angina at rest) and particularly marked clinical pictures or impending angina pectoris attacks or acute hypertensive crisis, the fast-acting (10 mg) Adalat capsules should be used. Once the situation has improved, an attempt may be made to transfer to Adalat retard tablets. The light-sensitive active substance in the sustained release tablet is protected from light both inside and outside the packaging; nonetheless the tablets should only be removed from the foil immediately before use and should not be broken. Presentations: Adalat retard: packs with 30, 50 and 100 sustained release tablets containing 20 mg nifedipine. Hospital packs.

Bayer AG, Leverkusen, West-Germany. Co.-No.: 2 w

E 7/021

Bayer

BAYER